Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy

Inclusion Criteria:

* Male and Females aged \> 18 years.
* Naïve to chemotherapy.
* Patients planned to receive at least 2 cycles of highly emetogenic treatments with cisplatin in single dose \> 50 mg/m2 every 21 or 28 days.
* Willing and able to understand and sign informed consent and complete the patient diary.

Exclusion Criteria:

* Presence of brain symptomatic metastases (in case of small, asymptomatic metastases and in absence of steroids treatment, the patient is eligible).
* Scheduled to receive or having received in the past 4 weeks radiation treatment to brain, abdomen or pelvis.
* Emesis or significant nausea within 24 hours before first chemotherapy cycle.
* Known hypersensitivity reaction to Ginger or any components of the product.
* Patients with coagulopathies causing potential increase risk of bleeding.
* Patients on therapy with oral anticoagulants.
* Planned surgery procedures in the period of the study or within 2 weeks after the study conclusion.
* History of seizures.
* Active use of cannabinoids.
* Known current or past drug or alcohol abuse.
* Use of other investigational drugs within 30 days before study entry or during the study.
* Clinically significant findings on physical exam or presence of known clinically significant disease that would interfere with study evaluation